medwireNews: The EMA has recommended European use of the first-in-class, dual-action medication tirzepatide for glucose lowering in people with type 2 diabetes.
It is indicated as an adjunct to diet and exercise in combination with other glucose-lowering treatments, and can be used as a monotherapy in people who cannot use metformin.
The decision is based on findings from the five clinical trials so far published from the SURPASS series. These showed significantly greater glucose reductions with tirzepatide compared with placebo, semaglutide, and insulin degludec and glargine in various study populations, as well as substantial reductions in bodyweight.
The cardiovascular outcomes trial – SURPASS-CVOT – is ongoing.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group